Format

Send to

Choose Destination
Lancet Oncol. 2009 Oct;10(10):975-80. doi: 10.1016/S1470-2045(09)70227-X.

Development of therapeutic HPV vaccines.

Author information

1
Johns Hopkins University Hospital, Baltimore, MD, USA. ctrimbl@jhmi.edu

Abstract

At least 15% of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.

PMID:
19796749
PMCID:
PMC3090037
DOI:
10.1016/S1470-2045(09)70227-X
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center